The efficacy and safety of ustekinumab in adolescents newly diagnosed with type 1 diabetes: the USTEK1D RCT

The efficacy and safety of ustekinumab in adolescents newly diagnosed with type 1 diabetes: the USTEK1D RCT

Background Type 1 diabetes is an autoimmune disease affecting over 400,000 children and adults in the United Kingdom for which currently the only available therapy is insulin. Objective(s) To determine the efficacy and safety of the monoclonal antibody ustekinumab targeting the interleukin 12/interl...

Full description

Bibliographic Details
Main Authors: Kymberley Carter, Wai-Yee Cheung, Hayley A Hutchings, Greg Fegan, Gail Holland, Steve Luzio, Gareth Dunseath, Stephen Hiles, Susie Marques-Jones, John W Gregory, Danijela Tatovic, Peter Taylor, Jane Bowen-Morris, Rachel Stenson, Stephanie Hanna, Zainab Mahmood, Jennie Yang, Evangelia Williams, Timothy Tree, Ashish Marwaha, Colin M Dayan
Format: Article
Language:English
Published: NIHR Journals Library 2025-02-01
Series:Efficacy and Mechanism Evaluation
Subjects:
diabetes mellitus type 1
randomised controlled trial
ustekinumab
c-peptide
Online Access:https://doi.org/10.3310/FQLN7416

Internet

https://doi.org/10.3310/FQLN7416

Similar Items